November 19, 2020 -- Artificial intelligence-powered biotech and drug discovery platform AbCellera has purchased Trianni for $90 million. The deal boosts AbCellera's ability to create large human antibody databases for drug discovery.
Trianni develops humanized mice used in drug trials, AbCellera said. Its mice help drug developers investigate multispecific antibodies and immune tolerance as well as target new epitopes.
Adding Trianni to its business expands AbCellera's platform, which currently includes microfluidic single-cell screening, repertoire sequencing, and bispecific protein engineering, according to the firm.